Momelotinib bei Myelofibrose und An ämie
Acta Haematol. 2024 Mar 11;147(2):254-256. doi: 10.1159/000538289. Online ahead of print.NO ABSTRACTPMID:38467116 | DOI:10.1159/000538289 (Source: Acta Haematologica)
Source: Acta Haematologica - March 11, 2024 Category: Hematology Source Type: research
The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-na ïve chronic lymphocytic leukemia patients
CONCLUSIONS: MBI was associated with prolonged LDT and TFS in patients with CLL in the w&w phase. These results provide a basis for a larger randomized-control trial.PMID:38461815 | DOI:10.1159/000538055 (Source: Acta Haematologica)
Source: Acta Haematologica - March 10, 2024 Category: Hematology Authors: Shirley Shapira Naama Hirschberger Yishai Ofran Barak Mizrahi Esti Mandel Ohad Benjamini Noa Rabinowicz Adi Zoref-Lorenz Source Type: research
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma
Acta Haematol. 2024 Mar 6. doi: 10.1159/000538047. Online ahead of print.ABSTRACTBispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a su...
Source: Acta Haematologica - March 6, 2024 Category: Hematology Authors: Alexander D Heini Vera Ulrike Bacher Dilara Akhoundova Katja Seipel Thomas Pabst Source Type: research
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma
Acta Haematol. 2024 Mar 6. doi: 10.1159/000538047. Online ahead of print.ABSTRACTBispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a su...
Source: Acta Haematologica - March 6, 2024 Category: Hematology Authors: Alexander D Heini Vera Ulrike Bacher Dilara Akhoundova Katja Seipel Thomas Pabst Source Type: research
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma
Acta Haematol. 2024 Mar 6. doi: 10.1159/000538047. Online ahead of print.ABSTRACTBispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a su...
Source: Acta Haematologica - March 6, 2024 Category: Hematology Authors: Alexander D Heini Vera Ulrike Bacher Dilara Akhoundova Katja Seipel Thomas Pabst Source Type: research
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma
Acta Haematol. 2024 Mar 6. doi: 10.1159/000538047. Online ahead of print.ABSTRACTBispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a su...
Source: Acta Haematologica - March 6, 2024 Category: Hematology Authors: Alexander D Heini Vera Ulrike Bacher Dilara Akhoundova Katja Seipel Thomas Pabst Source Type: research
Primary nodal Epstein-Barr virus-positive T-cell/NK-cell lymphoma: Real-world experience
In conclusion, in the context of PTCL-EBV, despite a limited sample size, the ICE/Dexa regimen shows potential benefits in terms of ORR and PFS. Furthermore, the application of HSCT following the attainment of a complete response may prove advantageous.PMID:38432198 | DOI:10.1159/000537962 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Dae-Ho Choi Sang Eun Yoon Junhun Cho Seok Jin Kim Won Seog Kim Source Type: research
Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation
CONCLUSION: Our findings suggest that the effect of the patient HLA-B leader genotype is modified by the PTCy dose, providing immunological insight into the PTCy dosage and supporting further studies to investigate the underlying mechanisms.PMID:38432202 | DOI:10.1159/000538078 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Makoto Moriguchi Kentaro Ido Hiroshi Okamura Mika Nakamae Kazuki Sakatoku Yosuke Makuuchi Masatomo Kuno Teruhito Takakuwa Asao Hirose Mitsutaka Nishimoto Yasuhiro Nakashima Hideo Koh Masayuki Hino Hirohisa Nakamae Source Type: research
Venous thromboembolism prophylaxis in inflammatory bowel disease inpatients - Systematic review and meta-analysis
CONCLUSIONS: In studies with lower-risk-of-bias, a significant reduction in VTEs was shown in patients treated with VTE prophylaxis (NNT=35), which should be carefully considered against an increased major-bleeding risk (NNH=114). However current data is limited and randomized trials dedicated to IBD inpatients would aid in understating whether universal prophylaxis should be recommended.PMID:38432204 | DOI:10.1159/000538086 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Rotem McNeil Danielle Fredman Ofir Eldar Anat Gafter-Gvili Tomer Avni Source Type: research
Primary nodal Epstein-Barr virus-positive T-cell/NK-cell lymphoma: Real-world experience
In conclusion, in the context of PTCL-EBV, despite a limited sample size, the ICE/Dexa regimen shows potential benefits in terms of ORR and PFS. Furthermore, the application of HSCT following the attainment of a complete response may prove advantageous.PMID:38432198 | DOI:10.1159/000537962 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Dae-Ho Choi Sang Eun Yoon Junhun Cho Seok Jin Kim Won Seog Kim Source Type: research
Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation
CONCLUSION: Our findings suggest that the effect of the patient HLA-B leader genotype is modified by the PTCy dose, providing immunological insight into the PTCy dosage and supporting further studies to investigate the underlying mechanisms.PMID:38432202 | DOI:10.1159/000538078 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Makoto Moriguchi Kentaro Ido Hiroshi Okamura Mika Nakamae Kazuki Sakatoku Yosuke Makuuchi Masatomo Kuno Teruhito Takakuwa Asao Hirose Mitsutaka Nishimoto Yasuhiro Nakashima Hideo Koh Masayuki Hino Hirohisa Nakamae Source Type: research
Venous thromboembolism prophylaxis in inflammatory bowel disease inpatients - Systematic review and meta-analysis
CONCLUSIONS: In studies with lower-risk-of-bias, a significant reduction in VTEs was shown in patients treated with VTE prophylaxis (NNT=35), which should be carefully considered against an increased major-bleeding risk (NNH=114). However current data is limited and randomized trials dedicated to IBD inpatients would aid in understating whether universal prophylaxis should be recommended.PMID:38432204 | DOI:10.1159/000538086 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Rotem McNeil Danielle Fredman Ofir Eldar Anat Gafter-Gvili Tomer Avni Source Type: research
Primary nodal Epstein-Barr virus-positive T-cell/NK-cell lymphoma: Real-world experience
In conclusion, in the context of PTCL-EBV, despite a limited sample size, the ICE/Dexa regimen shows potential benefits in terms of ORR and PFS. Furthermore, the application of HSCT following the attainment of a complete response may prove advantageous.PMID:38432198 | DOI:10.1159/000537962 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Dae-Ho Choi Sang Eun Yoon Junhun Cho Seok Jin Kim Won Seog Kim Source Type: research
Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation
CONCLUSION: Our findings suggest that the effect of the patient HLA-B leader genotype is modified by the PTCy dose, providing immunological insight into the PTCy dosage and supporting further studies to investigate the underlying mechanisms.PMID:38432202 | DOI:10.1159/000538078 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Makoto Moriguchi Kentaro Ido Hiroshi Okamura Mika Nakamae Kazuki Sakatoku Yosuke Makuuchi Masatomo Kuno Teruhito Takakuwa Asao Hirose Mitsutaka Nishimoto Yasuhiro Nakashima Hideo Koh Masayuki Hino Hirohisa Nakamae Source Type: research
Venous thromboembolism prophylaxis in inflammatory bowel disease inpatients - Systematic review and meta-analysis
CONCLUSIONS: In studies with lower-risk-of-bias, a significant reduction in VTEs was shown in patients treated with VTE prophylaxis (NNT=35), which should be carefully considered against an increased major-bleeding risk (NNH=114). However current data is limited and randomized trials dedicated to IBD inpatients would aid in understating whether universal prophylaxis should be recommended.PMID:38432204 | DOI:10.1159/000538086 (Source: Acta Haematologica)
Source: Acta Haematologica - March 3, 2024 Category: Hematology Authors: Rotem McNeil Danielle Fredman Ofir Eldar Anat Gafter-Gvili Tomer Avni Source Type: research
